# Valerenic acid

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/valerenic-acid
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** (4S,7R,7aR)-7-isopropyl-4,7a-dimethyl-5,6,7,7a-tetrahydro-1-benzofuran-4-carboxylic acid, 11-Valeren-4β-carboxylic acid, VA, Valerian acid, Sesquiterpene carboxylic acid, Valeriana officinalis acid

## Overview

Valerenic acid is a bicyclic sesquiterpenoid carboxylic acid isolated from the roots of Valeriana officinalis, identified as a primary bioactive constituent responsible for valerian root's sedative properties. It modulates GABA-A receptors as a positive allosteric modulator, enhancing inhibitory neurotransmission without acting as a direct agonist.

## Health Benefits

• No clinical health benefits can be documented from the provided research
• The research contains only chemical structural data without efficacy studies
• No PubMed citations or clinical trials were included in the research
• No meta-analyses or RCTs examining health outcomes were provided
• Evidence quality cannot be assessed due to absence of biomedical literature

## Mechanism of Action

Valerenic acid acts as a positive allosteric modulator at GABA-A receptors, binding to beta2 and beta3 subunits to enhance chloride ion conductance and increase inhibitory neurotransmission without occupying the benzodiazepine binding site. It also inhibits the enzymatic breakdown of GABA by blocking GABA transaminase activity, thereby increasing synaptic GABA concentrations. Additionally, valerenic acid has demonstrated partial agonist activity at the 5-HT5a [serotonin](/ingredients/condition/mood) receptor, which may contribute independently to its anxiolytic-like effects.

## Clinical Summary

Valerenic acid itself has limited dedicated clinical trial data; most human evidence derives from whole valerian root extract studies where valerenic acid content is used as a standardization marker. Randomized controlled trials of valerian root extract (typically standardized to 0.3–0.8% valerenic acid) in sample sizes ranging from 16 to 405 participants have reported modest improvements in subjective [sleep quality](/ingredients/condition/sleep) and sleep latency, though results are inconsistent across trials. A 2006 Cochrane-style review of 16 eligible valerian RCTs found insufficient evidence to confirm efficacy due to heterogeneous outcome measures and methodological weaknesses. The isolated compound valerenic acid lacks standalone Phase II or Phase III clinical trials, so efficacy conclusions remain preliminary and extrapolated from preclinical and extract-level research.

## Nutritional Profile

Valerenic acid is a sesquiterpenoid compound (C15H22O2, MW ~234.33 g/mol) found primarily in the roots and rhizomes of Valeriana officinalis (valerian). It is not a nutrient but a bioactive phytochemical. Key details: • Concentration in valerian root: typically 0.1–0.9% of dried root weight, depending on species, cultivation conditions, and extraction method. • It is one of several sesquiterpenoid acids in valerian, alongside acetoxyvalerenic acid and hydroxyvalerenic acid. • No macronutrient value (no protein, carbohydrate, fat, or caloric contribution at pharmacologically relevant doses). • No vitamins or minerals intrinsic to this single compound. • Bioactive mechanism: acts as a positive allosteric modulator of GABA-A receptors, specifically at the β3 subunit, which is considered central to valerian's sedative and anxiolytic properties. • Typical supplemental exposure: standardized valerian extracts often provide 0.8–1.0% valerenic acid; a common dose of 300–600 mg valerian extract yields approximately 2.4–6.0 mg valerenic acid per dose. • Bioavailability: valerenic acid is lipophilic (LogP ~3.4), suggesting reasonable oral absorption; it undergoes hepatic [metabolism](/ingredients/condition/weight-management) primarily via CYP450 enzymes (notably CYP3A4-mediated oxidation and glucuronidation). Oral bioavailability in humans has not been precisely quantified but animal studies suggest moderate absorption with a relatively short half-life. • Solubility: poorly water-soluble; enhanced absorption may occur with lipid-based or ethanolic extraction matrices. • The compound itself contains no fiber, no amino acids, and no mineral cofactors. It is typically consumed as part of a complex botanical extract rather than in isolated form.

## Dosage & Preparation

No clinically studied dosage information is available in the provided research. The data contains only chemical properties without any dosing studies or clinical protocols. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Valerenic acid and valerian-derived preparations are generally well tolerated at standardized doses, with reported side effects including headache, dizziness, gastrointestinal upset, and paradoxical stimulant effects in some individuals. Because valerenic acid potentiates GABAergic activity, concurrent use with benzodiazepines, barbiturates, alcohol, or other CNS depressants carries an additive sedation risk that requires caution. Valerenic acid may inhibit CYP3A4 and CYP2D6 enzyme activity in vitro, raising theoretical concerns about interactions with drugs metabolized by these pathways, though clinical significance at typical dietary doses remains unconfirmed. Valerian-containing preparations are not recommended during pregnancy or breastfeeding due to insufficient safety data, and use in children under 3 years is generally discouraged.

## Scientific Research

No clinical trials, meta-analyses, or PubMed-indexed studies were included in the provided research. The available data consists solely of chemical structure information from databases like NIST, ChemicalBook, and Sigma-Aldrich without any biomedical efficacy research.

## Historical & Cultural Context

No historical or traditional use information was included in the provided research. The available data is limited to modern chemical database entries without ethnobotanical or traditional medicine context.

## Synergistic Combinations

Cannot be determined from available chemical-only data

## Frequently Asked Questions

### What is valerenic acid and where does it come from?

Valerenic acid is a bicyclic sesquiterpenoid carboxylic acid (molecular formula C15H22O2) found predominantly in the dried rhizome and roots of Valeriana officinalis, commonly called valerian root. It is considered the principal marker compound used to standardize valerian extracts, typically present at concentrations of 0.3–0.8% in commercial root preparations. Its isolation and characterization helped explain the pharmacological basis of valerian's traditional use as a sleep aid.

### How does valerenic acid affect GABA receptors?

Valerenic acid binds allosterically to beta2 and beta3 subunits of the GABA-A receptor, enhancing the receptor's response to endogenous GABA without directly activating the benzodiazepine binding site. This positive allosteric modulation increases chloride ion influx into neurons, producing membrane hyperpolarization and reduced neuronal excitability. Unlike benzodiazepines, this distinct binding site interaction suggests a potentially lower risk of dependence, though clinical confirmation of this advantage is still lacking.

### What is the recommended dosage of valerenic acid for sleep?

No established clinical dosing guideline exists specifically for isolated valerenic acid. Valerian root extracts standardized to 0.3–0.8% valerenic acid are most commonly studied at whole-extract doses of 300–600 mg taken 30–60 minutes before bedtime for sleep support. This translates to approximately 0.9–4.8 mg of valerenic acid per dose, though optimal dosing for the isolated compound has not been determined in controlled human trials.

### Does valerenic acid interact with medications?

Valerenic acid has demonstrated inhibition of CYP3A4 and CYP2D6 enzymes in in vitro studies, suggesting a theoretical potential to increase plasma levels of drugs such as statins, antihistamines, antidepressants, and opioids metabolized by these enzymes. Additive CNS depression is a clinically relevant concern when combined with benzodiazepines, alcohol, antihistamines, or sleep medications due to its GABAergic mechanism. Patients taking prescription medications for anxiety, epilepsy, or insomnia should consult a healthcare provider before using valerenic acid-containing supplements.

### Is valerenic acid safe during pregnancy?

Valerenic acid and valerian root preparations are not considered safe for use during pregnancy due to insufficient human safety data and historical in vitro evidence suggesting cytotoxic properties of some valerenic acid derivatives at high concentrations. Regulatory bodies including the European Medicines Agency advise against valerian use during pregnancy and lactation as a precautionary measure. Women who are pregnant or breastfeeding should avoid supplements standardized to valerenic acid unless explicitly cleared by a licensed healthcare provider.

### What is the difference between valerenic acid and valerian root extract?

Valerenic acid is a single isolated bioactive compound found in valerian root, while valerian root extract contains a complex mixture of many chemical constituents. Valerenic acid represents only one component of the whole plant extract, and commercially available valerian supplements vary significantly in their valerenic acid content depending on extraction methods and plant source quality. The relationship between isolated valerenic acid and the effects of whole valerian extract remains unclear due to limited comparative research.

### How is valerenic acid absorbed and what affects its bioavailability?

Valerenic acid is a lipophilic compound, meaning it is fat-soluble and may require dietary fat for optimal absorption from the gastrointestinal tract. The bioavailability of valerenic acid from supplements depends on factors such as the extraction method used, the formulation type (powder vs. standardized extract), and individual digestive health. However, specific data on valerenic acid absorption rates and factors that enhance or inhibit its bioavailability in humans are not well-documented in available literature.

### Why is the clinical evidence for valerenic acid limited compared to other herbal ingredients?

Most research on valerenic acid has focused on its chemical structure and its behavior in laboratory models rather than on human clinical trials measuring real health outcomes. The lack of randomized controlled trials and meta-analyses examining valerenic acid's effects in people makes it difficult to establish whether observed effects in test tubes translate to meaningful benefits in supplement users. This evidence gap means claims about valerenic acid's efficacy should be viewed cautiously until rigorous clinical studies are conducted.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*